Full Professorship (W3) for Signaling-Based Precision Oncology
Veröffentlicht am(vor 28 Tagen)
Bewerbungsende(in 14 Tagen)
Charité Universitätsmedizin Berlin / German Cancer Research CenterBerlin
The Charité Universitätsmedizin Berlin and the German Cancer Research Center (DKFZ) jointly invite applications for the following
Full Professorship W3
for Signaling-Based Precision Oncology
(Salary Group:W3 BBesG – tenured)
Reference Number: 131/2018
The position is to be filled at the partner site Berlin of the German Cancer Consortium (DKTK). According to the "Jülicher Modell" the
successful candidate will be appointed as a full professor of the Charité – Universitätsmedizin and will be granted leave of absence
in order to be employed at the DKFZ. Provided that all legal requirements aremet, the candidate will get a civil servant status for life.
The translational oncology group will be located at the Charité and will be an integral part of the DKTK operations at this partner site.
We invite applications for a highly motivated candidate with an excellent scientific track record to build upamultidisciplinary
research team for translation of new developments in cancer research into clinical applications as defined by DKTK in its program
(http://www.dktk.org). The successful candidate should have an internationally recognized record of accomplishment, preferably in
the field of cancer-oriented functional omics analyses, a vision for an innovative research program and a strong motivation to interact
with research groups in basic, translational and clinical cancer research. Important prerequisites are cutting-edge contributions to
cancer research enabling efficient target identification/validation and drug evaluation as well as an enhanced understanding of
oncogenic signal transduction, complemented by expertise in the interpretation of complex cancer-related datasets.
Specific research fields to be strengthened in the near future at the DKTK partner site Berlin include:
genetic screening technologies in pre-clinical models and patient biomaterial
characterization of tumor heterogeneity
characterization of the tumor microenvironment
DNA damage response signaling/DNA replication stress
The successful candidate should hold expertise in one of the above areas. Additional research interfaces with immunotherapy applications
are considered to be a particularly valuable asset. Applicants should have an excellent publication record, a successful history
of funding acquisition and sound experience as a group leader.
Additional prerequisites are strong leadership and coordination skills, a strong motivation and a firm commitment to undergraduate
and graduate student education within Charité‘s model curriculum in medicine and/or the international master‘s program in molecular
medicine. The candidate should bring a strong willingness to contribute into existing coordinated research collaborations and
graduate schools of the Charité (www.charite.de) and the DKFZ (www.dkfz.de), the DKTK (www.dktk.org) and co-operations with the
scientific and clinical community of the Berlin Institute of Health (BIH), and other hospitals in Berlin and Brandenburg are expected.
Qualifications required according to § 100 of the Berlin Higher Education Act (BerlHG), junior professorship or postdoctoral thesis
(Habilitation), or equivalent scientific achievements and teaching qualifications. Completed university degree as well as doctorate
(Ph.D and/or M.D.) in medicine or natural sciences with significant post-doctoral experience.
Charité and DKFZ are committed to increasing the proportion of women among the scientific staff, therefore we strongly encourage
women to apply.Women will be given preference over equally qualified men (within the framework of the legal possibilities).
Candidates with immigrant background who fulfill the necessary requirements are explicitly encouraged to apply. Equally qualified
applicants with disabilities will be given preference.
Prof. Dr. Michael Baumann, Chairman and Scientific Director, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280,
69120 Heidelberg, Germany via the DKFZ online application portal (http://www.dkfz.de/jobs).
The German Cancer Consortium (DKTK) is a joint initiative of the German Federal Ministry of Education and
Research (BMBF), the participating states and the DKFZ. The alliance between the DKFZ as the core center and the
university partner sites in Berlin, Dresden, Essen/Düsseldorf, Frankfurt / Mainz, Freiburg,München and Tübingen
establishes joint translational cancer research units. The DKTK promotes interdisciplinary research approaches and
innovative clinical studies, which will contribute to improved prevention, diagnosis and faster implementation of
personalized therapies for cancer patients.
Erschienen in der ZEIT am 21. Juni 2018
Bitte beziehen Sie sich in Ihrer Bewerbung auf den Stellenmarkt
Um unsere Webseite optimal gestalten und fortlaufend verbessern zu können, verwenden wir Cookies. Durch die weitere Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Weitere Informationen sowie Hinweise dazu, wie Sie die Speicherung der Cookies verhindern können, finden Sie in unserer Datenschutzerklärung.